Eli Lilly Raises Annual Outlook as Second-Quarter Revenue Surges 48%

2026-08-05 companies

Indianapolis, Wednesday, 5 August 2026.
Eli Lilly raised its 2026 revenue guidance to $87 billion after second-quarter sales surged 48% to $23 billion, driven by $9.9 billion in Mounjaro revenue.

Strong Metabolic Sales Propel Financial Performance

In the second quarter of 2026, Eli Lilly and Company (NYSE: LLY) reported a substantial surge in its global revenue, reaching $22.974 billion, representing a 48% increase year-over-year compared to the same period in 2025 [1]. This impressive performance was primarily fueled by the company’s blockbuster metabolic treatments, notably its tirzepatide franchise [1][4]. The diabetes therapy Mounjaro saw its quarterly sales soar by 91% to reach $9.943 billion, while the weight-loss medication Zepbound brought in $4.928 billion, marking a 46% increase [1]. This surge in volume, which grew by 60% globally, successfully offset a 13% decline in realized prices during the quarter [1].

Global Markets and Analyst Projections

Regionally, the pharmaceutical giant experienced robust expansion, with U.S. revenues growing by 33% to reach $14.4 billion [1]. Meanwhile, international markets experienced an even sharper expansion, with sales outside the United States climbing 80% to $8.6 billion [1]. A key driver of this international growth was the inclusion of Mounjaro on China’s National Reimbursement Drug List (NRDL) [1]. This overall financial performance comfortably exceeded the consensus estimates of Wall Street analysts, who had projected second-quarter revenues to land around $20.62 billion to $20.69 billion [3][4][5].

Upgraded Guidance and Earnings Breakdown

Buoyed by this exceptional operational momentum, Eli Lilly’s management announced a significant raise to its full-year 2026 guidance on August 5, 2026 [1][2]. The company upgraded its full-year revenue expectations to a range of $85.0 billion to $87.0 billion, up from its previous guidance range of $82.0 billion to $85.0 billion [1][4]. Furthermore, the company updated its full-year non-GAAP earnings per share (EPS) guidance to a range of $35.50 to $36.50 [1]. This updated forecast reflects both strong market demand and the company’s confidence in expanding its manufacturing footprint [1][4].

Net Income Expansion and Strategic Milestones

Looking closer at the quarterly earnings, Eli Lilly reported a non-GAAP net income of $7.5 billion, representing a 31.579% increase compared to the $5.7 billion reported in the second quarter of 2025 [1]. This translated to a non-GAAP EPS of $8.38, compared to $6.31 in the year-ago period [1]. The reported GAAP EPS for the second quarter of 2026 stood at $7.94, representing a 26% increase year-over-year [1]. Both GAAP and non-GAAP figures for the quarter were affected by $3.03 per share in acquired in-process research and development (IPR&D) charges, which stem from the company’s active business development and acquisitions [1].

Strategic Acquisitions and Manufacturing Expansion

To sustain its long-term growth and meet the global demand for its therapies, Eli Lilly has aggressively expanded its pipeline and manufacturing capabilities [1][4]. During the second quarter of 2026, the company completed several notable acquisitions, including Orna Therapeutics, Inc., Ajax Therapeutics, Inc., Centessa Pharmaceuticals plc., and Kelonia Therapeutics, Inc. [1]. Following the end of the quarter, the company completed three additional acquisitions within its infectious disease portfolio [1]. On the manufacturing side, Eli Lilly committed an additional $4.5 billion to expand its production facilities in Indiana, aiming to resolve supply constraints and boost the output of its in-demand treatments [1].

Clinical and Regulatory Horizons

Simultaneously, the drugmaker continues to hit key clinical and regulatory milestones [1][2]. During the quarter, Eli Lilly secured U.S. FDA approval for its atopic dermatitis treatment Ebglyss on June 9, 2026, and European Commission approval for Jaypirca for chronic lymphocytic leukemia [1]. Looking forward, the company plans to submit a Biologics License Application (BLA) to the U.S. FDA for its highly anticipated next-generation weight-loss medicine, retatrutide, in the first quarter of 2027, having completed its clinical data package for obesity, obstructive sleep apnea, and knee osteoarthritis [1].

Sources

Eli Lilly Pharmaceuticals